Skip to main content
Premium Trial:

Request an Annual Quote

Amgen, NeoGenomics Partner to Expand Biomarker Testing Access in NSCLC

NEW YORK — Amgen said on Monday that it has partnered with NeoGenomics as part of a new program to expand biomarker testing access to all advanced or metastatic non-small cell lung cancer patients.

The new program, dubbed Biomarker Assist, consists of two efforts. Through the first part, the Next-Generation Sequencing Affordability Program, Amgen will provide financial assistance to advanced NSCLC patients facing out-of-pocket costs for comprehensive biomarker panels. To be eligible, patients must have commercial or private insurance and the NGS panel must include the KRAS gene.

Through the program's second part, the KRAS Single Gene Test Program, Thousand Oaks, California-based Amgen will cover the cost of Fort Myers, Florida-based NeoGenomics' single-gene tests for the KRAS G12C driver mutation for all patients with advanced or metastatic NSCLC regardless of their insurance status or results. Both programs will remain valid for testing performed through the end of the year.

"Unfortunately, many patients still do not receive biomarker testing due to barriers in education, access, and reimbursement," Darryl Sleep, Amgen's chief medical officer and senior VP of global medicine, said in a statement. "Amgen's Biomarker Assist program is designed to help more patients with advanced non-small cell lung cancer gain access to testing. NeoGenomics' KRAS Single Gene Test is an important component of this program."

The Scan

Panel Votes for COVID-19 Pill

A US Food and Drug Administration panel has voted to support the emergency use authorization of an antiviral pill for COVID-19 from Merck and Ridgeback Biotherapeutics, CNN says.

But Not Harm

New Scientist reports that UK bioethicists say that though gene editing may improve food production, it should not harm livestock welfare.

Effectiveness Drop Anticipated

Moderna's Stéphane Bancel predicts that that current SARS-CoV-2 vaccines may be less effective against the Omicron variant, the Financial Times reports.

Cell Studies of Human Chromatin Accessibility, SARS-CoV-2 Variants, Cell Signaling Networks

In Cell this week: chromatin accessibility maps of adult human tissues, modeling to track SARS-CoV-2 variants of concern, and more.